

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when stem cell transplant is unsuitable [ID4014]

Final stakeholder list

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Janssen (daratumumab) <p><u>Patient/carer group</u></p> <ul style="list-style-type: none"> • Black Health Agency for Equality • Blood Cancer UK • Cancer Black Care • Cancer Equality • Cancer 52 • DKMS • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Leukaemia Cancer Society • Leukaemia CARE • Macmillan Cancer Support • Maggie's Centres • Marie Curie • Myeloma UK • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus Cancer Care <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • British Committee for Standards in Haematology • British Geriatrics Society • British Psychosocial Oncology Society • British Society for Haematology • Cancer Research UK • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Accord Healthcare (bortezomib, lenalidomide, thalidomide) • Advanz pharma (dexamethasone) • Aspen (dexamethasone) • Aspire (bortezomib, dexamethasone) • Bristol-Myers Squibb (lenalidomide) • Celgene (thalidomide) • Consilient health (dexamethasone) • Focus Pharmaceuticals (dexamethasone) • Hameln Pharmaceuticals

National Institute for Health and Care Excellence

Final matrix for the single technology appraisal of Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when stem cell transplant is unsuitable [ID4014]

Issue date: March 2022

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • UK Myeloma Forum • UK Clinical Pharmacy Association • UK Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • NHS Kingston CCG • NHS Lancashire North CCG • Welsh Government 	<p>(dexamethasone)</p> <ul style="list-style-type: none"> • Hospira (dexamethasone) • Janssen (bortezomib) • Martindale pharma (dexamethasone) • Merck, Sharp and Dohme (dexamethasone) • Mylan (bortezomib) • Piramal Critical Care (lenalidomide) • Rosemont Pharmaceuticals (dexamethasone) • Sandoz (bortezomib) • Teva (dexamethasone) • Thornton & Ross (bortezomib) • Zentiva (bortezomib) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Bone Cancer Research Trust • Cochrane Haematological Malignancies Group • Geonomics England • Institute of Cancer Research • Leukaemia UK • Leukaemia Busters • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do share it. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTees AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.